Phase 2 N=159 Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
Cachexia
Primary: The Efficacy of GTx-024 on Total Body Lean Mass. — 1.55; 0.98; 0.02 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Cachexia · Non-Small-Cell Lung Cancer · Pancreatic Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 10; 4 Participants
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
Phase 1 N=24 Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
Cachexia · Squamous Cell Carcinoma
Primary: Change in Total Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA) From Baseline to 7 Weeks. — -3.31; 1.42 Percent change
Phase 2 N=15 Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Cancer Cachexia
Primary: Change of Body Weight — 0; 0.2 kg
N/A N=539 Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.
Non-small Cell Lung Cancer · Cachexia
Primary: Frequency of Cachexia According to Modified Fearon Criteria — 173 Participants
N/A N=36 A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
Cancer Cachexia
Primary: Change in Serum Albumin — 4.0 g/dL
Phase 2 N=37 Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia
Primary: Proportion of Subjects With a Positive Change From Baseline to Week 4 in Lean Body Mass — 8; 6; 5; 3 participants
Phase 3 N=513 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Cachexia · Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 52; 56 percentage of participants
Phase 3 N=495 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Cachexia · Non-Small Cell Lung Cancer
Primary: Change in Lean Body Mass — 0.65; -0.98 kg — p=< 0.0001
Phase 3 N=484 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Cachexia · Non-Small Cell Lung Cancer
Primary: Change in Lean Body Mass — 0.99; -0.47 kg — p=< 0.0001
Phase 2 N=187 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Part A: Change From Baseline in Body Weight at Week 12 — NA; NA; NA; NA Kilogram
Phase 2 N=227 SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
Cachexia
Primary: Mean Change From Baseline to Day 85 in the Distance Walked During the 6 Minute Walk Test (MWT) Following Treatment With SUN11031 in Participants Having Cachexia…
Phase 2 N=57 Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Cachexia
Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 — 2.0; 0.65 Percentage Change of TMV
N/A N=469 Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Sarcopenia · Non Small Cell Lung Cancer · Malnutrition
Primary: Progression Free Survival (PFS) — 350; 773 days
Phase 3 N=318 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.938; 0.594 Change from baseline in body weight (kg) — p=<0.0001
Phase 3 N=318 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.822; 0.538 kg — p=<0.0001
Phase 3 N=73 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
Gastrointestinal Cancer · Lung Cancer
Primary: Change in Appetite as Measured by ESAS — -0.83; -1.19 units on a scale
Phase 2 N=67 BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24 — 5.87; 0.02; 7.01; -0.65 Percentage Change of TMV — p=<0.001
N/A N=129 Parenteral Hydration in Advanced Cancer Patients
Advanced Cancer · Dehydration
Primary: Participant Reduced Symptom Burden — -3.3; -2.8 units on a scale
N/A N=60 The Effectiveness and Mechanism Study of Auricular Needling in Treating Cancer Induced Anorexia
Anorexia Nervosa · Cancer
Primary: Simple Appetite Questionnaire — 8.7; 9.57; 11.26; 9.93 score on a scale
Phase 1 N=18 Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A — 2.45; 1.84 Units on a Scale
Phase 3 N=376 Levocarnitine in Treating Fatigue in Cancer Patients
Fatigue · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks — -0.96; -1.11 units on a scale — p=0.57
Phase 3 N=43 Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
Advanced Cancer
Primary: Functional Assessment of Cancer Therapy-Fatigue Subscale (FACIT-F) at Day 29 (+/- 3 Days) — 12; 13; 12; 14 units on a scale
Phase 2 N=23 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Locally Advanced Unresectable Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Adenocarcinoma
Primary: Weight Stability — -1.98; -5.58 Percent weight change
Phase 1 N=66 Marijuana in Combination With Opioids in Palliative and Hospice Patients
Pain
Primary: Primary Reduction of Pain — 2.55; 1.40 units on a scale from 0 to 10
Phase 3 N=72 Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer
Cancer · Fatigue
Primary: Fatigue as Measured by the Physical Fatigue Scale in the The Multidimensional Fatigue Inventory (MFI) (Smets EM, Garssen B, Bonke B, et al., J Psychosom Res 39:315-325…
N/A N=22 Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors
Breast Cancer
Primary: Maximal Calcium-activated Tension Single Muscle Fiber Tension — 185; 172; 172; 168 milliNewtons per millimeter^2
Phase 2 N=31 The Effects of Thalidomide on Symptom Clusters
Advanced Cancers
Primary: Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS) — 3; 3; 4; 3 units on a scale
N/A N=17 Ketogenic Diet in Advanced Cancer
Cancer
Primary: To Determine the Safety and Tolerability of a Modified Low Carbohydrate Diet in People With Advanced Cancer Across Different Tumor Types. — 11 participants